Murray Laugesen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Murray Laugesen has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Jefferson Fowles
3 shared publications- Chris Bullen
National Institute for Health Innovation, University of Auckland, Auckland, New Zealand
2 shared publications - Marewa Glover
Centre of Research Excellence: Indigenous Sovereignty & Smoking, Auckland, New Zealand
2 shared publications - Robert Scragg
School of Population Health, The University of Auckland, Auckland, New Zealand
2 shared publications B Linehan
Medlab, Hamilton, New Zealand
1 shared publicationB Swinburn
1 shared publication
Latest Publications
- Open Access
- 8 March 2013
- Published by Springer Nature in BMC Public Health
- Vol. 13 (1) , 210
Study protocol for a randomised controlled trial of electronic cigarettes versus nicotine patch for smoking cessation
Electronic cigarettes (e-cigarettes or electronic nicotine delivery systems [ENDS]) are electrically powered devices generally similar in appearance to a cigarette that deliver a propylene glycol and/or glycerol mist to the airway of users when drawing on the mouthpiece. Nicotine and other substances such as flavourings may be included in the fluid vaporised by the device. People report using e-cigarettes to help quit smoking and studies of their effects on tobacco withdrawal and craving suggest good potential as smoking cessation aids. However, to date there have been no adequately powered randomised trials investigating their cessation efficacy or safety. This paper outlines the protocol for this study.
- 8 March 2013
- Published by Springer Nature in BMC Public Health
- Vol. 13 (1) , 210
Open AccessStudy protocol for a randomised controlled trial of electronic cigarettes versus nicotine patch for smoking cessation
Electronic cigarettes (e-cigarettes or electronic nicotine delivery systems [ENDS]) are electrically powered devices generally similar in appearance to a cigarette that deliver a propylene glycol and/or glycerol mist to the airway of users when drawing on the mouthpiece. Nicotine and other substances such as flavourings may be included in the fluid vaporised by the device. People report using e-cigarettes to help quit smoking and studies of their effects on tobacco withdrawal and craving suggest good potential as smoking cessation aids. However, to date there have been no adequately powered randomised trials investigating their cessation efficacy or safety. This paper outlines the protocol for this study.
- Open Access
- 18 June 2009
- Published by Springer Nature in BMC Public Health
- Vol. 9 (1) , 194
Hand-rolled cigarette smoking patterns compared with factory-made cigarette smoking in New Zealand men
Roll-your-own (RYO) cigarettes have increased in popularity, yet their comparative potential toxicity is uncertain. This study compares smoking of RYO and factory-made (FM) cigarettes on smoking pattern and immediate potential toxicity.
- 18 June 2009
- Published by Springer Nature in BMC Public Health
- Vol. 9 (1) , 194
Open AccessHand-rolled cigarette smoking patterns compared with factory-made cigarette smoking in New Zealand men
Roll-your-own (RYO) cigarettes have increased in popularity, yet their comparative potential toxicity is uncertain. This study compares smoking of RYO and factory-made (FM) cigarettes on smoking pattern and immediate potential toxicity.
- 1 February 2009
- Published by BMJ in Tobacco Control
- Vol. 18 (1) , 29-33
Cigarette fires and burns in a population of New Zealand smokers
Objectives: To identify the proportion of adult cigarette smokers who have experienced cigarette-caused fires and burns and to describe smoker characteristics associated with increased risk of cigarette-caused fires and burns. Methods: Data on cigarette-caused fires and burns were collected in the baseline questionnaire of a randomised trial of a smoking cessation intervention conducted in New Zealand between March 2006 and May 2007. Participants were adult callers to a national smoking cessation counselling service. Lifetime prevalence estimates of cigarette-caused fires and burns were obtained and associations between smoker characteristics and risk of fires and burns examined using logistic regression. Results: Of 1097 participants in the trial at baseline, 75 (6.8%) reported past experience of ⩾1 fires caused by cigarettes (96 fires reported in total) and 658 (60.0%) described at least 1 cigarette-caused burn. In all, 57 participants (5.2%) reported burns that required medical attention. Male sex and Māori ethnicity (indigenous New Zealanders, who comprise 15% of the national population and among whom 42% of adults are smokers) were associated with increased risk of cigarette-caused fires. Male sex, younger age, younger age of smoking initiation, being unmarried, having a partner who smoked, having a higher education level and an annual income of $20 000 or more were associated with increased risk of cigarette burn injuries. Conclusions: The results indicate that cigarette-caused fires and burns are common among New Zealand smokers, are a source of inequality and therefore deserve greater attention from health advocates and policymakers.
- 1 February 2009
- Published by BMJ in Tobacco Control
- Vol. 18 (1) , 29-33
Cigarette fires and burns in a population of New Zealand smokers
Objectives: To identify the proportion of adult cigarette smokers who have experienced cigarette-caused fires and burns and to describe smoker characteristics associated with increased risk of cigarette-caused fires and burns. Methods: Data on cigarette-caused fires and burns were collected in the baseline questionnaire of a randomised trial of a smoking cessation intervention conducted in New Zealand between March 2006 and May 2007. Participants were adult callers to a national smoking cessation counselling service. Lifetime prevalence estimates of cigarette-caused fires and burns were obtained and associations between smoker characteristics and risk of fires and burns examined using logistic regression. Results: Of 1097 participants in the trial at baseline, 75 (6.8%) reported past experience of ⩾1 fires caused by cigarettes (96 fires reported in total) and 658 (60.0%) described at least 1 cigarette-caused burn. In all, 57 participants (5.2%) reported burns that required medical attention. Male sex and Māori ethnicity (indigenous New Zealanders, who comprise 15% of the national population and among whom 42% of adults are smokers) were associated with increased risk of cigarette-caused fires. Male sex, younger age, younger age of smoking initiation, being unmarried, having a partner who smoked, having a higher education level and an annual income of $20 000 or more were associated with increased risk of cigarette burn injuries. Conclusions: The results indicate that cigarette-caused fires and burns are common among New Zealand smokers, are a source of inequality and therefore deserve greater attention from health advocates and policymakers.
- 15 June 2007
- Vol. 120 (1256) , U2587
Snuffing out cigarette sales and the smoking deaths epidemic.
Smokers need new products and policies to escape smoking's risks. And the next generation needs policies that will better protect them from becoming smokers. Low-nitrosamine tobacco snuff (hereafter termed 'snuff') is 20 times less dangerous than cigarette smoking. Its sale as nasal snuff raises the question as to how long cigarettes, including cigars and pipe tobacco, should continue to be sold and allowed to hasten the deaths of 4000 New Zealanders annually. Oral snuff has helped to reduce smoking to unusually low levels in Swedish men, is much less dangerous than smoking, and does not cause lung or mouth cancer. Moreover, smokeless tobacco (which includes snuff) could reduce smoking-caused health inequity for Maori. Snuff can improve population health, and more so if more smokers switch to it. Continued bans on snuff are now regarded by some experts as unsound public policy. Added to the mountain of evidence against cigarettes, sufficient evidence now exists for Government to use snuff to create safer tobacco choices for smokers, end cigarette sales altogether, and thus end the cigarette smoking deaths epidemic--in which 200,000 New Zealanders have died so far. The New Zealand Government can: Fund media campaigns to inform smokers of their new choices, and to urge them to quit smoking. (The 2007 Budget commits an extra $11 million per year for 4 years, an excellent start.) Regulate for warnings on snuff cans stating that snuff is "addictive but much safer than smoking", and regulate imports to only permit reduced-risk low-nitrosamine products. Tax each class of tobacco products proportionate to the respective risks of each. (Tax cigarettes at 20 times the snuff rate, instead of at the same rate.) Legislate, to expand the Smoke-free Environments Act's aims to include ending the sale of cigarettes and ending smoking deaths--i.e: Allow oral snuff to compete with cigarettes for market share (and for the smoker's nicotine receptors). Reduce addiction to smoking, by decreasing the nicotine content of cigarettes by 5% every 6 months. (Below 20% of current levels, most smokers will quit or switch to snuff.), Allot cigarette supply quotas to manufacturers and importers, decreasing by 5% every 6 months, on the grounds that cigarette smoke is irremediably toxic. The summed effects of these changes could end cigarette sales within 10 years, and prevent 90% of cigarette deaths within 22 years thereafter.
- 15 June 2007
- Vol. 120 (1256) , U2587
Snuffing out cigarette sales and the smoking deaths epidemic.
Smokers need new products and policies to escape smoking's risks. And the next generation needs policies that will better protect them from becoming smokers. Low-nitrosamine tobacco snuff (hereafter termed 'snuff') is 20 times less dangerous than cigarette smoking. Its sale as nasal snuff raises the question as to how long cigarettes, including cigars and pipe tobacco, should continue to be sold and allowed to hasten the deaths of 4000 New Zealanders annually. Oral snuff has helped to reduce smoking to unusually low levels in Swedish men, is much less dangerous than smoking, and does not cause lung or mouth cancer. Moreover, smokeless tobacco (which includes snuff) could reduce smoking-caused health inequity for Maori. Snuff can improve population health, and more so if more smokers switch to it. Continued bans on snuff are now regarded by some experts as unsound public policy. Added to the mountain of evidence against cigarettes, sufficient evidence now exists for Government to use snuff to create safer tobacco choices for smokers, end cigarette sales altogether, and thus end the cigarette smoking deaths epidemic--in which 200,000 New Zealanders have died so far. The New Zealand Government can: Fund media campaigns to inform smokers of their new choices, and to urge them to quit smoking. (The 2007 Budget commits an extra $11 million per year for 4 years, an excellent start.) Regulate for warnings on snuff cans stating that snuff is "addictive but much safer than smoking", and regulate imports to only permit reduced-risk low-nitrosamine products. Tax each class of tobacco products proportionate to the respective risks of each. (Tax cigarettes at 20 times the snuff rate, instead of at the same rate.) Legislate, to expand the Smoke-free Environments Act's aims to include ending the sale of cigarettes and ending smoking deaths--i.e: Allow oral snuff to compete with cigarettes for market share (and for the smoker's nicotine receptors). Reduce addiction to smoking, by decreasing the nicotine content of cigarettes by 5% every 6 months. (Below 20% of current levels, most smokers will quit or switch to snuff.), Allot cigarette supply quotas to manufacturers and importers, decreasing by 5% every 6 months, on the grounds that cigarette smoke is irremediably toxic. The summed effects of these changes could end cigarette sales within 10 years, and prevent 90% of cigarette deaths within 22 years thereafter.
- 27 November 2006
- Published by BMJ in Tobacco Control
- Vol. 15 (6) , 430-435
Marlboro UltraSmooth: a potentially reduced exposure cigarette?
Aim: To compare relative toxic emissions scores (RTE) of the carbon filter cigarette Marlboro UltraSmooth (MUS), against regular Marlboro, Holiday, and British Columbian brands. Method: MUS cigarettes were purchased in Tampa, Florida; Marlboro regular and Holiday were purchased in Auckland, New Zealand, and all emissions tested by Labstat International Inc, Kitchener, Ontario under Health Canada Intensive (HCI) machine-smoking conditions (55 ml puff per 30 seconds, filter ventilation holes blocked) against: (1) previous same brand emissions tested under ISO (International Organization for Standardization) conditions; (2) ISO and HCI average emissions for 16 regular brands sold in British Columbia (BC), the reference standard. Toxicants, selected by toxicological risk assessment, enabled estimation of an RTE per brand, and RTE per mg of nicotine. Results: The BC standard for RTE in both ISO and HCI test modes, including metals and nitrosamines, was set at 100. Hereafter excluding them, RTE in ISO mode for BC was 97, MUS 4, Marlboro 102, and Holiday regular 99; and in HCI test mode BC was 97, MUS 42, Marlboro regular 107, and Holiday 95. From ISO to HCI, MUS total puff volume increased 50%, from 252 ml to 380 ml; nicotine yield increased 2.6 fold. Normalising for nicotine (RTE per mg nicotine), in ISO test mode, the BC standard was 97, MUS 10, Marlboro regular 124, and Holiday regular 107. In HCI mode, however, MUS/nicotine at 104 exceeded the average BC standard of 97; Marlboro regular was 137, and Holiday regular 97; MUS ranked sixth highest among 18 regular brands. MUS contained 103 mg of carbon in its 304 mg filter, which was 55% ventilated. Conclusion: The combined acetate-carbon filter of MUS performed best at low smoke volumes on ISO testing. Under more smoker-realistic intensive machine testing, and correcting for relative nicotine concentration and compensatory smoking, MUS increased the RTE, for all toxicants combined, for carcinogens, and for cardiovascular toxicants, compared with most regular brands. MUS was not a potentially reduced-exposure product (PREP) under smoker-realistic test conditions, and thus would not be expected to reduce overall harm. It is unrealistic to expect that even major design changes, as seen in MUS, or a regulatory framework to enforce such changes, could reduce cigarette smoking mortality risks to acceptable levels.
- 27 November 2006
- Published by BMJ in Tobacco Control
- Vol. 15 (6) , 430-435
Marlboro UltraSmooth: a potentially reduced exposure cigarette?
Aim: To compare relative toxic emissions scores (RTE) of the carbon filter cigarette Marlboro UltraSmooth (MUS), against regular Marlboro, Holiday, and British Columbian brands. Method: MUS cigarettes were purchased in Tampa, Florida; Marlboro regular and Holiday were purchased in Auckland, New Zealand, and all emissions tested by Labstat International Inc, Kitchener, Ontario under Health Canada Intensive (HCI) machine-smoking conditions (55 ml puff per 30 seconds, filter ventilation holes blocked) against: (1) previous same brand emissions tested under ISO (International Organization for Standardization) conditions; (2) ISO and HCI average emissions for 16 regular brands sold in British Columbia (BC), the reference standard. Toxicants, selected by toxicological risk assessment, enabled estimation of an RTE per brand, and RTE per mg of nicotine. Results: The BC standard for RTE in both ISO and HCI test modes, including metals and nitrosamines, was set at 100. Hereafter excluding them, RTE in ISO mode for BC was 97, MUS 4, Marlboro 102, and Holiday regular 99; and in HCI test mode BC was 97, MUS 42, Marlboro regular 107, and Holiday 95. From ISO to HCI, MUS total puff volume increased 50%, from 252 ml to 380 ml; nicotine yield increased 2.6 fold. Normalising for nicotine (RTE per mg nicotine), in ISO test mode, the BC standard was 97, MUS 10, Marlboro regular 124, and Holiday regular 107. In HCI mode, however, MUS/nicotine at 104 exceeded the average BC standard of 97; Marlboro regular was 137, and Holiday regular 97; MUS ranked sixth highest among 18 regular brands. MUS contained 103 mg of carbon in its 304 mg filter, which was 55% ventilated. Conclusion: The combined acetate-carbon filter of MUS performed best at low smoke volumes on ISO testing. Under more smoker-realistic intensive machine testing, and correcting for relative nicotine concentration and compensatory smoking, MUS increased the RTE, for all toxicants combined, for carcinogens, and for cardiovascular toxicants, compared with most regular brands. MUS was not a potentially reduced-exposure product (PREP) under smoker-realistic test conditions, and thus would not be expected to reduce overall harm. It is unrealistic to expect that even major design changes, as seen in MUS, or a regulatory framework to enforce such changes, could reduce cigarette smoking mortality risks to acceptable levels.
- 25 November 2005
- Vol. 118 (1226) , U1751
Decreased red meat fat consumption in New Zealand: 1995-2002.
To review New Zealand red meat and meat fat supply trends before and after the introduction of the Quality Mark standard. Review of trends in: per capita meat fat supply estimates from the Food and Agriculture Organization (FAO); carcase and meat cut composition reports of knife dissection and chemical analyses; the fate of fat trim; and a Lincoln College study of home-cooked and trimmed beef. Intervention From September 1997, the red meat industry's Quality Mark required trimming of beef and lamb cuts to no more than 5 mm external fat. (1) Trimming of fat from red meat before sale (supported by virtually all butchers) decreased the fat and saturated fat content of a red meat carcase by 30% (beef, -27%; lamb, -30%; tallow unchanged); by -8% in the total food supply; and by -17% across all meat. In 2002, fat comprised 7.4% of trimmed beef cuts, and 11.2% of all beef sold: cuts, mince, or sausages. In 2002, fat comprised 15.3% of lamb cuts; and 15.5% with mince included. (2) From 1995 to 2002, total saturated fat availability per capita in the food supply decreased by 19% (from 65 g to 53 g per day), mostly due to 7 g less saturated fat daily from red meat. (3) When combining effects (1) and (2), saturated fat per capita decreased: -27% in total food supply; -65% in red meat excluding tallow; -48% in red meat including tallow. In 1995 (without trimming), red meat contributed 25% of saturated fat in the total food supply whereas in 2002, red meat contributed 19% before (and 13% after) trimming. (4) Home trimming may remove an additional 27% of fat from beef steaks. Centralised meat processing, and Quality Mark labelling since 1997, ensured fat was trimmed from beef and lamb cuts, and reduced saturated fat in red meats by 30%. In 2002, mince and sausages accounted for nearly half of beef fat sold as red meat.
- 25 November 2005
- Vol. 118 (1226) , U1751
Decreased red meat fat consumption in New Zealand: 1995-2002.
To review New Zealand red meat and meat fat supply trends before and after the introduction of the Quality Mark standard. Review of trends in: per capita meat fat supply estimates from the Food and Agriculture Organization (FAO); carcase and meat cut composition reports of knife dissection and chemical analyses; the fate of fat trim; and a Lincoln College study of home-cooked and trimmed beef. Intervention From September 1997, the red meat industry's Quality Mark required trimming of beef and lamb cuts to no more than 5 mm external fat. (1) Trimming of fat from red meat before sale (supported by virtually all butchers) decreased the fat and saturated fat content of a red meat carcase by 30% (beef, -27%; lamb, -30%; tallow unchanged); by -8% in the total food supply; and by -17% across all meat. In 2002, fat comprised 7.4% of trimmed beef cuts, and 11.2% of all beef sold: cuts, mince, or sausages. In 2002, fat comprised 15.3% of lamb cuts; and 15.5% with mince included. (2) From 1995 to 2002, total saturated fat availability per capita in the food supply decreased by 19% (from 65 g to 53 g per day), mostly due to 7 g less saturated fat daily from red meat. (3) When combining effects (1) and (2), saturated fat per capita decreased: -27% in total food supply; -65% in red meat excluding tallow; -48% in red meat including tallow. In 1995 (without trimming), red meat contributed 25% of saturated fat in the total food supply whereas in 2002, red meat contributed 19% before (and 13% after) trimming. (4) Home trimming may remove an additional 27% of fat from beef steaks. Centralised meat processing, and Quality Mark labelling since 1997, ensured fat was trimmed from beef and lamb cuts, and reduced saturated fat in red meats by 30%. In 2002, mince and sausages accounted for nearly half of beef fat sold as red meat.
- 15 April 2005
- Vol. 118 (1213) , U1401
Scope for regulation of cigarette smoke toxicity according to brand differences in published toxicant emissions.
To explore the scope for regulating to reduce the toxicity of manufactured cigarettes sold in New Zealand (NZ), based on published toxicant emissions by brand. Internet searches of published cigarette smoke emissions of 13 toxicants chosen on risk assessment principles, for 20 British Columbian, 15 Australian brands, and one NZ brand, Holiday Extra-mild (HEM), tested by Health Canada intensive smoke machine method at Labstat Inc, Kitchener, Ontario, as a ratio of toxicant to nicotine yield. We estimated relative overall smoke toxicity per disease group and per brand, after adjusting for the published cigarette-attributed mortality fractions for cancer, cardiovascular, and respiratory disease. After allowing for nicotine yield, filter ventilation, and compensatory over-smoking, there were significant differences between brands, with the NZ brand estimated to be the most toxic. Low-yield cigarettes (<0.9 mg nicotine ISO) were estimated to be on average 19% more potent overall than medium-yield cigarettes (p<0.01). Of toxicants identified and measurable in smoke; 1,3-butadiene accounted for 45% of cancer potency; hydrogen cyanide for 89% of cardiovascular; and acrolein for 97% of respiratory potency--these three toxicants accounting for 65% of identified brand potency. Individual toxicant emissions varied across brands by a factor of 1.5 for carbon monoxide, to 32 for lead. Compared with HEM, one Canadian brand, 'Export A full flavor', carried a 37% lower cancer risk. This lower risk was largely due to differences in nicotine yield, lowering the toxicant/nicotine ratio. Cigarettes, unregulated, are unduly dangerous. Though many smoke toxicants cannot yet be quantified, risk assessment based on current data suggests that regulation could partly reduce identifiable cancer risk, and possibly eliminate the excess cardiovascular and respiratory toxicity of HEM, when compared with regular Canadian brands. The first goal should be to reduce emissions of the leading three toxicants, in addition to more effective charcoal filters. Tobacco smoke, unlike unburnt or non-smoking tobacco, contains toxic gases and trillions of reactive oxygen species molecules per puff, and will remain inherently harmful. Regulation could usefully part-reduce smoke toxicity exposure for continuing smokers, while not relenting on efforts to assist smokers and society to be quit of smoking.
- 15 April 2005
- Vol. 118 (1213) , U1401
Scope for regulation of cigarette smoke toxicity according to brand differences in published toxicant emissions.
To explore the scope for regulating to reduce the toxicity of manufactured cigarettes sold in New Zealand (NZ), based on published toxicant emissions by brand. Internet searches of published cigarette smoke emissions of 13 toxicants chosen on risk assessment principles, for 20 British Columbian, 15 Australian brands, and one NZ brand, Holiday Extra-mild (HEM), tested by Health Canada intensive smoke machine method at Labstat Inc, Kitchener, Ontario, as a ratio of toxicant to nicotine yield. We estimated relative overall smoke toxicity per disease group and per brand, after adjusting for the published cigarette-attributed mortality fractions for cancer, cardiovascular, and respiratory disease. After allowing for nicotine yield, filter ventilation, and compensatory over-smoking, there were significant differences between brands, with the NZ brand estimated to be the most toxic. Low-yield cigarettes (<0.9 mg nicotine ISO) were estimated to be on average 19% more potent overall than medium-yield cigarettes (p<0.01). Of toxicants identified and measurable in smoke; 1,3-butadiene accounted for 45% of cancer potency; hydrogen cyanide for 89% of cardiovascular; and acrolein for 97% of respiratory potency--these three toxicants accounting for 65% of identified brand potency. Individual toxicant emissions varied across brands by a factor of 1.5 for carbon monoxide, to 32 for lead. Compared with HEM, one Canadian brand, 'Export A full flavor', carried a 37% lower cancer risk. This lower risk was largely due to differences in nicotine yield, lowering the toxicant/nicotine ratio. Cigarettes, unregulated, are unduly dangerous. Though many smoke toxicants cannot yet be quantified, risk assessment based on current data suggests that regulation could partly reduce identifiable cancer risk, and possibly eliminate the excess cardiovascular and respiratory toxicity of HEM, when compared with regular Canadian brands. The first goal should be to reduce emissions of the leading three toxicants, in addition to more effective charcoal filters. Tobacco smoke, unlike unburnt or non-smoking tobacco, contains toxic gases and trillions of reactive oxygen species molecules per puff, and will remain inherently harmful. Regulation could usefully part-reduce smoke toxicity exposure for continuing smokers, while not relenting on efforts to assist smokers and society to be quit of smoking.
- 15 April 2005
- Vol. 118 (1213) , U1402
Scope for regulation of cigarette smoke toxicity: the case for including charcoal filters.
To compare the emissions toxicity of two manufactured cigarette brands, one with and one without a charcoal filter, in the light of manufacturers' laboratory research findings on the properties of charcoal filters. Emissions of Mild Seven charcoal filter brands, regular (labelled '12 mg tar') and Light (labelled '9 mg tar') purchased in 2004, were compared with those of Holiday Extra-mild brand (9 mg tar, acetate filter), purchased in 2002. All emissions were tested under intensive machine smoking conditions by Labstat International Inc., Kitchener, Ontario. The Mild Seven brands contained a small amount of charcoal, its black granules visible against the white acetate filter. The charcoal filter in the brands tested did not reduce toxicity to the extent expected, though they gave significantly lower emissions for the respiratory-toxicants acrolein (14%-17% lower, p 'less than and equal to' 0.01) and formaldehyde (26-37% lower, p 'less than and equal to' 0.01). Reductions were not significant for acetaldehyde, and actually higher for hydrogen cyanide. Overall, estimated cardiovascular-respiratory toxicity was not reduced, whether based on toxicant emissions or the toxicant to nicotine ratios. Of the packet labels, neither tar yield (mg) nor the descriptors 'mild', 'light', or 'extra-mild', or 'charcoal filter' for these three brands was associated with any reduction of the combined respiratory--and cardiovascular toxicity of mainstream smoke, as measured by leading toxicants tested by the intensive method. Previously secret documents from cigarette companies, including British American Tobacco, reported reductions of 75%-80% in hydrogen cyanide, acetaldehyde, acrolein, and formaldehyde in mainstream smoke from addition of charcoal to the filter. We estimated that an effective charcoal filter could reduce a brand's overall relative toxicity score for identifiable toxicant by over 40%. Since 1965, major cigarette firms have known from their chemists that many smoke toxicants, including hydrogen cyanide and acrolein, were removable by manufacturing the cigarette with a charcoal filter. To this day, few brands have charcoal filters. The best known, Mild Seven, contained a token charcoal filter only. In neither Japan nor New Zealand did this brand lower cardiovascular toxicant emissions in smoke. In the Smoke-free Environments Act, Government has the power to lower smoke emissions by regulation, but no regulations are in place. The Act does not give power to add filters to cigarettes, but does give power to lower smoke emissions to the level attainable by using a charcoal filter, which could reduce smoke emission toxicity to a large extent. Regulation to require effective charcoal filters is now long overdue.
- 15 April 2005
- Vol. 118 (1213) , U1402
Scope for regulation of cigarette smoke toxicity: the case for including charcoal filters.
To compare the emissions toxicity of two manufactured cigarette brands, one with and one without a charcoal filter, in the light of manufacturers' laboratory research findings on the properties of charcoal filters. Emissions of Mild Seven charcoal filter brands, regular (labelled '12 mg tar') and Light (labelled '9 mg tar') purchased in 2004, were compared with those of Holiday Extra-mild brand (9 mg tar, acetate filter), purchased in 2002. All emissions were tested under intensive machine smoking conditions by Labstat International Inc., Kitchener, Ontario. The Mild Seven brands contained a small amount of charcoal, its black granules visible against the white acetate filter. The charcoal filter in the brands tested did not reduce toxicity to the extent expected, though they gave significantly lower emissions for the respiratory-toxicants acrolein (14%-17% lower, p 'less than and equal to' 0.01) and formaldehyde (26-37% lower, p 'less than and equal to' 0.01). Reductions were not significant for acetaldehyde, and actually higher for hydrogen cyanide. Overall, estimated cardiovascular-respiratory toxicity was not reduced, whether based on toxicant emissions or the toxicant to nicotine ratios. Of the packet labels, neither tar yield (mg) nor the descriptors 'mild', 'light', or 'extra-mild', or 'charcoal filter' for these three brands was associated with any reduction of the combined respiratory--and cardiovascular toxicity of mainstream smoke, as measured by leading toxicants tested by the intensive method. Previously secret documents from cigarette companies, including British American Tobacco, reported reductions of 75%-80% in hydrogen cyanide, acetaldehyde, acrolein, and formaldehyde in mainstream smoke from addition of charcoal to the filter. We estimated that an effective charcoal filter could reduce a brand's overall relative toxicity score for identifiable toxicant by over 40%. Since 1965, major cigarette firms have known from their chemists that many smoke toxicants, including hydrogen cyanide and acrolein, were removable by manufacturing the cigarette with a charcoal filter. To this day, few brands have charcoal filters. The best known, Mild Seven, contained a token charcoal filter only. In neither Japan nor New Zealand did this brand lower cardiovascular toxicant emissions in smoke. In the Smoke-free Environments Act, Government has the power to lower smoke emissions by regulation, but no regulations are in place. The Act does not give power to add filters to cigarettes, but does give power to lower smoke emissions to the level attainable by using a charcoal filter, which could reduce smoke emission toxicity to a large extent. Regulation to require effective charcoal filters is now long overdue.
- Open Access
- 5 December 2003
- Published by BMJ in Tobacco Control
- Vol. 12 (4) , 406-410
Hand rolling cigarette papers as the reference point for regulating cigarette fire safety
Aim:To compare the burning characteristics of the tobacco and paper of manufactured and hand rolled cigarettes, and set a fire safety standard of manufacture to largely reduce the fire risk from discarded cigarettes.Methods:(1) Cigarette extinction test of ignition strength: 40 cigarettes per brand, lit and placed on 15 layers of filter paper, in accordance with ASTM test standard E2187-02. (2) Citrate extracted by 0.1N hydrochloric acid from cigarette papers and from tobacco in manufactured cigarettes, the supernatant analysed by high performance liquid chromatography using ultraviolet visual light spectrophotometer. (3) Survey of 750 nationally representative adults age 18 years and over, by telephone, including 184 smokers.Materials:(a) New Zealand made Holiday, and Horizon, and US made Marlboro manufactured cigarettes; (b) US manufactured Merit with banded paper; (c) Holiday, Horizon and Marlboro hand rolling tobaccos, hand rolled in Rizla cigarette papers; (d) manufactured cigarettes as in (a), reconstructed using Rizla hand rolling cigarette papers.Results:1. (a) For each brand of manufactured cigarettes, 40/40 burnt full length; (b) for Merit banded paper cigarettes 29/40 (73%) burnt full length; (c) for each brand of hand rolled cigarettes 0/40 burnt full length; (d) 0/40 manufactured cigarettes reconstructed with Rizla hand rolling paper burnt full length. 2. Citrate content: (a) In manufactured cigarette papers: 0.3–0.8 mg; in tobacco of manufactured cigarettes: Holiday 0, Horizon 0, Marlboro 8.8 mg; (b) Merit: in banded paper 0.418 mg; in tobacco 10.23 mg; (c) In hand rolled cigarettes: in the papers < 0.08 mg; in hand rolled tobacco 13.3–15.0 mg; (d) In hand rolling papers of reconstructed cigarettes: < 0.018 mg. 3. Requiring manufactured cigarettes to compulsorily self-extinguish when left unattended was supported by 67% of smokers, 61% of manufactured cigarette smokers, 82% of hand rolled smokers, and by 68% of non-smokers.Conclusion:The wrapping paper is a key determinant of whether or not unpuffed cigarettes burn their full length. Using international test methods, popular brands of manufactured cigarettes all burnt full length, but none did so when re-wrapped in hand rolling cigarette paper. This provides a ready-to-hand smoker acceptable standard for reducing ignition potential from manufactured cigarettes, as a basis for regulation or litigation.
- 5 December 2003
- Published by BMJ in Tobacco Control
- Vol. 12 (4) , 406-410
Open AccessHand rolling cigarette papers as the reference point for regulating cigarette fire safety
Aim:To compare the burning characteristics of the tobacco and paper of manufactured and hand rolled cigarettes, and set a fire safety standard of manufacture to largely reduce the fire risk from discarded cigarettes.Methods:(1) Cigarette extinction test of ignition strength: 40 cigarettes per brand, lit and placed on 15 layers of filter paper, in accordance with ASTM test standard E2187-02. (2) Citrate extracted by 0.1N hydrochloric acid from cigarette papers and from tobacco in manufactured cigarettes, the supernatant analysed by high performance liquid chromatography using ultraviolet visual light spectrophotometer. (3) Survey of 750 nationally representative adults age 18 years and over, by telephone, including 184 smokers.Materials:(a) New Zealand made Holiday, and Horizon, and US made Marlboro manufactured cigarettes; (b) US manufactured Merit with banded paper; (c) Holiday, Horizon and Marlboro hand rolling tobaccos, hand rolled in Rizla cigarette papers; (d) manufactured cigarettes as in (a), reconstructed using Rizla hand rolling cigarette papers.Results:1. (a) For each brand of manufactured cigarettes, 40/40 burnt full length; (b) for Merit banded paper cigarettes 29/40 (73%) burnt full length; (c) for each brand of hand rolled cigarettes 0/40 burnt full length; (d) 0/40 manufactured cigarettes reconstructed with Rizla hand rolling paper burnt full length. 2. Citrate content: (a) In manufactured cigarette papers: 0.3–0.8 mg; in tobacco of manufactured cigarettes: Holiday 0, Horizon 0, Marlboro 8.8 mg; (b) Merit: in banded paper 0.418 mg; in tobacco 10.23 mg; (c) In hand rolled cigarettes: in the papers < 0.08 mg; in hand rolled tobacco 13.3–15.0 mg; (d) In hand rolling papers of reconstructed cigarettes: < 0.018 mg. 3. Requiring manufactured cigarettes to compulsorily self-extinguish when left unattended was supported by 67% of smokers, 61% of manufactured cigarette smokers, 82% of hand rolled smokers, and by 68% of non-smokers.Conclusion:The wrapping paper is a key determinant of whether or not unpuffed cigarettes burn their full length. Using international test methods, popular brands of manufactured cigarettes all burnt full length, but none did so when re-wrapped in hand rolling cigarette paper. This provides a ready-to-hand smoker acceptable standard for reducing ignition potential from manufactured cigarettes, as a basis for regulation or litigation.
- 24 January 2003
- Vol. 116 (1168) , U295
Ischaemic heart disease, Type 1 diabetes, and cow milk A1 beta-casein.
To test the correlation of per capita A1 beta-casein (A1/capita) and milk protein with: 1) ischaemic heart disease (IHD) mortality; 2) Type 1 (insulin-dependent) diabetes mellitus (DM-1) incidence. A1/capita was estimated as the product of per capita cow milk and cream supply and its A1 beta-casein content (A1/beta) (calculated from herd tests and breed distribution, or from tests of commercial milk), then tested for correlation with: 1) IHD five years later in 1980, 1985, 1990 and 1995, in 20 countries which spent at least US $1000 (purchasing power parities) per capita in 1995 on healthcare; 2) DM-1 at age 0-14 years in 1990-4 (51 were surveyed by WHO DiaMond Project; 19 had A1 data). For comparison, we also correlated 77 food, and 110 nutritive supply FAO (Food and Agriculture Organization)-based measures, against IHD and DM-1. For IHD, cow milk proteins (A1/capita, r = 0.76, p <0.001; A1/capita including cheese, r = 0.66; milk protein r = 0.60, p = 0.005) had stronger positive correlations with IHD five years later, than fat supply variables, such as the atherogenic index (r = 0.50), and myristic, the 14-carbon saturated fat (r = 0.48, p <0.05). The Hegsted scores for estimating serum cholesterol (r = 0.42); saturated fat (r = 0.37); and total dairy fat (r = 0.31) were not significant for IHD in 1995. Across the 20 countries, a 1% change in A1/capita in 1990 was associated with a 0.57% change in IHD in 1995. A1/capita correlations were stronger for male than female mortality. On multiple regression of A1/capita and other food supply variables in 1990, only A1/capita was significantly correlated with IHD in 1995. DM-1 was correlated with supply of: A1/capita in milk and cream (r = 0.92, p <0.00001); milk and cream protein excluding cheese (r = 0.68, p <0.0001); and with A1/beta in milk and cream (r = 0.47, p <0.05). Correlations were not significant for A2, B or C variants of milk beta-casein. DM-1 incidence at 0-4, 5-9 and 10-14 years was equally correlated (r = 0.80, 0.81, 0.81 respectively) with milk protein supply. A 1% change in A1/capita was associated with a 1.3% change in DM-1 in the same direction. Cow A1 beta-casein per capita supply in milk and cream (A1/capita) was significantly and positively correlated with IHD in 20 affluent countries five years later over a 20-year period--providing an alternative hypothesis to explain the high IHD mortality rates in northern compared to southern Europe. For DM-1, this study confirms Elliott's 1999 correlation on 10 countries for A1/capita,1 but not for B beta-casein/capita. Surveys of A1 beta-casein consumption in two-year-old Nordic children, and some casein animal feeding experiments, confirm the A1/capita and milk protein/capita correlations. They raise the possibility that intensive dairy cattle breeding may have emphasised a genetic variant in milk with adverse effects in humans. Further animal research and clinical trials would be needed to compare disease risks of A1-free versus 'ordinary' milk.
- 24 January 2003
- Vol. 116 (1168) , U295
Ischaemic heart disease, Type 1 diabetes, and cow milk A1 beta-casein.
To test the correlation of per capita A1 beta-casein (A1/capita) and milk protein with: 1) ischaemic heart disease (IHD) mortality; 2) Type 1 (insulin-dependent) diabetes mellitus (DM-1) incidence. A1/capita was estimated as the product of per capita cow milk and cream supply and its A1 beta-casein content (A1/beta) (calculated from herd tests and breed distribution, or from tests of commercial milk), then tested for correlation with: 1) IHD five years later in 1980, 1985, 1990 and 1995, in 20 countries which spent at least US $1000 (purchasing power parities) per capita in 1995 on healthcare; 2) DM-1 at age 0-14 years in 1990-4 (51 were surveyed by WHO DiaMond Project; 19 had A1 data). For comparison, we also correlated 77 food, and 110 nutritive supply FAO (Food and Agriculture Organization)-based measures, against IHD and DM-1. For IHD, cow milk proteins (A1/capita, r = 0.76, p <0.001; A1/capita including cheese, r = 0.66; milk protein r = 0.60, p = 0.005) had stronger positive correlations with IHD five years later, than fat supply variables, such as the atherogenic index (r = 0.50), and myristic, the 14-carbon saturated fat (r = 0.48, p <0.05). The Hegsted scores for estimating serum cholesterol (r = 0.42); saturated fat (r = 0.37); and total dairy fat (r = 0.31) were not significant for IHD in 1995. Across the 20 countries, a 1% change in A1/capita in 1990 was associated with a 0.57% change in IHD in 1995. A1/capita correlations were stronger for male than female mortality. On multiple regression of A1/capita and other food supply variables in 1990, only A1/capita was significantly correlated with IHD in 1995. DM-1 was correlated with supply of: A1/capita in milk and cream (r = 0.92, p <0.00001); milk and cream protein excluding cheese (r = 0.68, p <0.0001); and with A1/beta in milk and cream (r = 0.47, p <0.05). Correlations were not significant for A2, B or C variants of milk beta-casein. DM-1 incidence at 0-4, 5-9 and 10-14 years was equally correlated (r = 0.80, 0.81, 0.81 respectively) with milk protein supply. A 1% change in A1/capita was associated with a 1.3% change in DM-1 in the same direction. Cow A1 beta-casein per capita supply in milk and cream (A1/capita) was significantly and positively correlated with IHD in 20 affluent countries five years later over a 20-year period--providing an alternative hypothesis to explain the high IHD mortality rates in northern compared to southern Europe. For DM-1, this study confirms Elliott's 1999 correlation on 10 countries for A1/capita,1 but not for B beta-casein/capita. Surveys of A1 beta-casein consumption in two-year-old Nordic children, and some casein animal feeding experiments, confirm the A1/capita and milk protein/capita correlations. They raise the possibility that intensive dairy cattle breeding may have emphasised a genetic variant in milk with adverse effects in humans. Further animal research and clinical trials would be needed to compare disease risks of A1-free versus 'ordinary' milk.